Total Neoadjuvant Therapy for Pancreatic Cancer—What Is Totality?
Author:
Affiliation:
1. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia
Abstract
Publisher
American Medical Association (AMA)
Link
https://jamanetwork.com/journals/jamasurgery/articlepdf/2817943/jamasurgery_cannas_2024_it_240001_1719948214.68157.pdf
Reference7 articles.
1. Total neoadjuvant therapy for operable pancreatic cancer.;Kim;Ann Surg Oncol,2021
2. Added value of radiotherapy following neoadjuvant FOLFIRINOX for Resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis.;Janssen;Ann Surg Oncol,2021
3. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial.;Murphy;JAMA Oncol,2018
4. Total Neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial.;Murphy;JAMA Oncol,2019
5. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer.;Truty;Ann Surg,2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3